A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Wugen, Inc.
Wugen, Inc.
Celgene
Daiichi Sankyo
Boehringer Ingelheim
HUYABIO International, LLC.
Kyowa Kirin Co., Ltd.
Atara Biotherapeutics
Hebei Senlang Biotechnology Inc., Ltd.
miRagen Therapeutics, Inc.
Eli Lilly and Company
Bristol-Myers Squibb
GlaxoSmithKline
Progen Pharmaceuticals
Morphotek
GlaxoSmithKline
INSYS Therapeutics Inc